Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis

Company Overview

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative therapies for rare neuromuscular and pulmonary diseases. Headquartered in Pratteln, Switzerland, the company concentrates on addressing high unmet medical needs in conditions such as Duchenne muscular dystrophy (DMD), limb‐girdle muscular dystrophies and other mitochondrial or neuromuscular disorders. Santhera’s corporate strategy emphasizes both in‐house development and strategic partnerships to advance its drug candidates through clinical trials and bring approved therapies to market.

The company’s flagship marketed product is Raxone (idebenone), a synthetic analogue of coenzyme Q10 that received marketing authorization in Europe for the treatment of visual impairment in patients with Leber’s hereditary optic neuropathy (LHON). In addition to Raxone’s role in LHON, Santhera has expanded the use of idebenone under the brand name Puldysa in certain European countries for the maintenance of respiratory function in patients with DMD. Santhera’s pipeline includes vamorolone, a novel corticosteroid analogue being developed in collaboration with ReveraGen BioPharma for boys with DMD, as well as earlier‐stage programs targeting rare mitochondrial and muscle disorders.

Santhera serves patients and healthcare providers across Europe and North America through a network of subsidiaries and distribution partners. The company was founded in the mid‐1990s and maintains research and commercial operations in key markets, including Germany, Italy and the United States. Santhera continues to leverage its expertise in rare disease drug development, regulatory strategy and patient advocacy to expand its portfolio and reach, aiming to deliver new treatment options for underserved patient populations.

Key Stats

• Today's Range: $18.40 to $18.40
• 50-Day Range: $14.75 to $18.40
• 52-Week Range: $14.75 to $19.00
• Volume: N/A
• Average Volume: 229 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Santhera Pharmaceuticals Stock Analysis - MarketRank™

Santhera Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Santhera Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Santhera Pharmaceuticals is -13.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Santhera Pharmaceuticals is -13.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Santhera Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Santhera Pharmaceuticals has recently decreased by 42.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Santhera Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Santhera Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Santhera Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Santhera Pharmaceuticals has recently decreased by 42.86%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Santhera Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Santhera Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 8.23% of the stock of Santhera Pharmaceuticals is held by institutions.

SPHDF Stock Analysis - Frequently Asked Questions

How have SPHDF shares performed this year?

Santhera Pharmaceuticals' stock was trading at $9.42 at the beginning of the year. Since then, SPHDF shares have increased by 95.3% and is now trading at $18.40.

When did Santhera Pharmaceuticals' stock split?

Santhera Pharmaceuticals shares reverse split on the morning of Monday, July 3rd 2023.The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Santhera Pharmaceuticals?

Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SPHDF
• CIK: N/A
• Web: www.santhera.com
• Phone: (161) 906-8950
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A